Anti-Tumour Response to Modified Self-Epitopes
AssigneeScancell Limited
InventorsLinda Gillian Durrant, Victoria Anne Brentville, Rachael Louise Metheringham
Life of this patent
Estimating the term…
Abstract
Anti-tumour immune responses to modified self-epitopes. The present invention relates to the use of tumour-associated epitopes in medicine and in particular in the treatment of cancer. The epitopes stimulate an immune reaction against the tumour and have a modification selected from determination of arginine to citrulline, nitration of tyrosine, oxidation of tryptophan and deamination of glutamine or asparagine. The invention also relates to nucleic acids comprising sequences that encode such epitopes for use in the treatment of cancer.
Claims4
A tumour-associated epitope which stimulates an immune reaction against the tumour, the epitope having a modification selected from determination of arginine to citrulline, wherein the epitope is derived from cytokeratin 8.
Dependencies are inferred from the claim text.